Has David Kulber, MD received payments from drug or device companies?

Yes. Drug and device makers reported $194,166 in general payments to David Kulber, MD across 163 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Kulber, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Kulber, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Kulber, MD

Plastic and Reconstructive Surgery · Los Angeles, CANPI 1568474732

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $131,575 of the $194,166 with a category attached, or 67.8%. Musculoskeletal Transplant Foundation Inc. accounts for 93.9% of it on its own, with 16 other manufacturers making up the rest. Among plastic and reconstructive surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$194,166in general payments, 2019–2025

Across 163 payments — averaging $1191.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Musculoskeletal Transplant Foundation Inc.$182K
Micromed Inc$4K
Arthrex$2K
Saxum Surgical, Inc.$2K
Sientra, Inc.$1K
Polynovo North America LLC$1K
plus $2K from 11 others

$146,196in research payments, 2019–2025

Across 15 payments — averaging $9746.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Musculoskeletal Transplant Foundation Inc.$146K

What the payments were for

Consulting fees$16,1508%
Speaking & faculty fees$131,57568%
Travel & lodging$29,99615%
Food & beverage$11,5606%
Education$4,8853%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Musculoskeletal Transplant Foundation Inc.	93	$182,365
Micromed Inc	6	$3,790
Arthrex	2	$2,094
Saxum Surgical, Inc.	5	$1,527
Sientra, Inc.	14	$1,370
Polynovo North America LLC	9	$1,071
Integra Lifesciences Corporation	6	$582
Endo Pharmaceuticals Inc.	13	$483
Acell, Inc.	2	$229
Bioventus LLC	1	$163
Mentor Worldwide LLC	2	$159
BD	1	$146
Dynasplint Systems Inc.	3	$65
AbbVie	2	$43
Checkpoint Surgical, Inc	2	$39
Axogen	1	$28
Medline Industries LP	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INTEGRA$1,357
SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT$956
Novosorb BTM$785
INTEGRA DERMAL REGENERATION TEMPLATE$516
PRIMATRIX$325
XIAFLEX$274
OMNIGRAFT$191
SURGIMEND$191
Exogen Ultrasound Bone Healing System$163
Phasix Mesh$146
MENTOR MemoryGel Resterilizable Gel Sizer$141
ARTOURA Breast Tissue Expander$141

How this compares

$194,166 in reported general payments places this provider in the 95th percentile of 349 plastic and reconstructive surgery providers in California.

See all plastic and reconstructive surgery providers in California →

Medicare billing

Part B allowed, 2024

$384,585

Medicare patients

521

Services billed

2,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	11	$98

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Los Angeles

Jeffrey HammoudehLos Angeles$159K
Steven AgafonoffLos Angeles$14K
Justine LeeLos Angeles$13K
Dan YaminiLos Angeles$11K
Reza JarrahyLos Angeles$10K
Nicholas DoLos Angeles$10K
Mark SuskiThousand Oaks$294K
Corey MaasSan Francisco$286K
Arian MowlaviLaguna Beach$250K
Charles LeeSan Francisco$200K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →